MedTrace Logo

GARDASIL Reexamination Study (V501-059)

NCT01062074 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3605

Last updated 2017-04-17

Study results available
· View outcomes & findings →

Summary

This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of Gardasil through collecting the safety information according to the Re-examination Regulation for New Drugs.

Conditions

  • Human Papillomavirus (HPV) Infection

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Eligibility

Min Age
9 Years
Max Age
26 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-28
Primary Completion
2013-05-07
Completion
2013-05-07

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01062074 on ClinicalTrials.gov